Lisata Therapeutics Inc (NASDAQ:LSTA) announced that it has won the “Overall BioPharma Solution of the Year” in the fifth annual BioTech Breakthrough Awards program conducted by BioTech Breakthrough, an independent market intelligence organization that evaluates and recognizes standout life sciences and biotechnology companies, products and services throughout the world.
The clinical-stage pharmaceutical company said the award is in recognition of its unique therapeutic approach and focused clinical development plans, designed to produce products to address the unmet medical needs of patients with advanced solid tumors.
“Winning the ‘Overall BioPharma Solution of the Year’ award further validates Lisata’s core mission and the groundbreaking potential of our CendR Platform to revolutionize the treatment of solid tumors and other diseases,” Lisata Therapeutics CEO David Mazzo said in a statement.
“This recognition belongs to the entire Lisata team and our partners who are dedicated to developing therapies that offer significantly better outcomes for patients.”
Through the company’s proprietary CendR Platform technology, which enables more effective tumor-targeted and tissue-penetrating delivery of anti-cancer drugs by activating the CendR transport mechanism, Lisata said it aims to improve the efficacy of existing standards-of-care and emerging anti-cancer therapies, including cytotoxics, immunotherapies, RNA-based treatments, and antibody-drug conjugates (ADCs).
It is the second consecutive year Lisata has been honored with a BioTech Breakthrough Award.